Signaling Pathway News and Research

RSS

Newly identified gene drives development of the second most common type of lung carcinoma

A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might someday be treated.

9 Jan 2023

Research suggests potential therapeutic avenues to enhance PD-1 immune checkpoint sensitivity

A new research paper was published in Oncotarget's Volume 13 on December 20, 2022, entitled, "Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression."

6 Jan 2023

Study details the “immunometabolic editing” mechanism of tumor evolution

A Ludwig Cancer Research study has discovered that the immune system's surveillance of cancer can itself induce metabolic adaptations in the cells of early-stage tumors that simultaneously promote their growth and equip them to suppress lethal immune responses.

5 Jan 2023

Exploring the immune mechanism induced by BCG vaccine in humanized mouse model

Announcing a new article publication for Zoonoses journal. This study was aimed at screening differentially expressed genes (DEGs) and exploring the potential immune mechanism induced by the Bacillus Calmette-Guerin (BCG) vaccine in a humanized mouse model.

3 Jan 2023

Researchers identify novel gene mechanism in most aggressive kidney cancers

In a new study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers driven by overexpression of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway with loss of the tuberous sclerosis complex (TSC) tumor suppressor gene.

3 Jan 2023

Why do some people develop persistent lung sequelae after severe COVID-19?

Clinical presentation following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from mild self-limiting illness to severe respiratory failure. Many studies have analyzed the early acute phases of coronavirus disease 2019(COVID-19), but few focused on the longer-term sequelae following infection.

2 Jan 2023

Cystic fibrosis drug shows promise to treat pneumonia

Pathogens such as SARS-CoV-2 and pneumococcus can cause severe pneumonia. If the airways then fill with fluid, the patient risks developing acute respiratory distress syndrome.

22 Dec 2022

Sotorasib achieves meaningful anticancer activity in patients with KRAS G12C-mutated metastatic pancreatic cancer

In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

21 Dec 2022

Inhibiting inflammatory signaling pathway could reduce the chances of heart disease in cancer survivors

Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York have discovered that common cancer treatments, such as radiotherapy or anthracycline drugs, cause long-term damage to heart tissue by activating a key inflammatory signaling pathway.

19 Dec 2022

Researchers discover how segmentation clock genes instruct the tempo of spine formation

One of the most dramatic phases of fetal development occurs as previously unstructured collections of rapidly dividing precursor cells begin forming the embryo's spine.

15 Dec 2022

Tiny messenger can be promising candidate for treatment of diseases associated with muscular atrophy

WNT messenger proteins are crucial for a variety of cellular functions. A specific WNT messenger can increase muscle mass and improve regeneration in skeletal muscle.

14 Dec 2022

The therapeutic effects and safety of psychedelics

Psychedelics are reported to have rapid-onset and long-lasting therapeutic benefits after a single or few doses.

14 Dec 2022

Signaling pathway within brain cells regulates sleep

A good night's sleep can work wonders for both mind and body. But what is it that determines how much we need to sleep, and what can cause us to sleep more deeply?

12 Dec 2022

Study reveals biological mechanism to explain why respiratory viruses spike in colder seasons

Researchers at Mass Eye and Ear and Northeastern University have discovered a previously unidentified immune response inside the nose that fights off viruses responsible for upper respiratory infections.

7 Dec 2022

Researchers discover new mechanism that enables cancer cells to move throughout the body

An international team of researchers has uncovered a new mechanism that enables cancer cells to move throughout the body, providing a potential new target to stop metastasis, which is responsible for 90 per cent of cancer deaths.

5 Dec 2022

Study implicates gut microbiome health in Parkinson's disease

A new study published in the journal Nature Communications discusses the links between this condition that affects the brain and changes in the gut microbiome that may predate brain changes.

1 Dec 2022

Pediatric acute myeloid leukemia genetic subtypes with poor outcomes show increased inflammatory cytokine signaling

Researchers used ribonucleic acid (RNA) sequence data to understand the association between inflammatory cytokines and poor outcomes of pediatric Acute Myeloid Leukemia (pAML).

29 Nov 2022

Glycan signatures in rheumatic diseases and their associated functional implications

A new paper examines the understanding of glycosylation in an array of rheumatic diseases and indicates the potential for therapeutic interventions using the same mechanism.

28 Nov 2022

Severe COVID-19 associated with an imbalance in key immune system signaling pathway

Researchers at the University of São Paulo in Brazil have found that severe COVID-19 is associated with an imbalance in an important immune system signaling pathway.

23 Nov 2022

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022